23 March 2020

Movember-funded prostate cancer study

Prostate cancer study could transform management of patients with aggressive cancer
Prostate Cancer | Where The Money Goes

A new type of scan that helps doctors understand whether a man’s prostate cancer has spread should be routinely used in those with high-risk disease, according to a Movember-funded study.
Results of the proPSMA study, published in The Lancet, showed that PSMA scans were more accurate than conventional CT/bone scans.

Professor Declan Murphy, the study’s senior author and Director of Genitourinary Cancer at Peter MacCallum Cancer Centre in Melbourne, Australia, said: “The proPSMA study will change practice with immediate effect. Having much more accurate information about a patient’s cancer, will enable prostate cancer specialists to recommend much more effective strategies to treat individual patients.”

During a PSMA scan, a small radioactive module is injected into a vein. It finds its way to prostate cancer cells and binds with them. The patient then goes into a PET scanner that takes images of the whole body and shows cancerous cells as small as 2-3mm.

The proPSMA study was funded by Movember via a partnership with the Prostate Cancer Foundation of Australia. The trial was supported and co-badged bythe Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP).

Dr Mark Buzza, global director of prostate cancer biomedical research at Movember said: “This is a really exciting development.  The results of this trial have shown that PSMA PET/CT scans are not only more accurate for staging previously untreated high-risk prostate cancer compared to currently used imaging techniques, but also men receive less radiation exposure compared with current imaging.

 “There is now solid evidence that PSMA PET/CT scans are the gold standard first-line imaging test for staging high-risk prostate cancer. We would like to see PSMA scans adopted into clinical practice as soon as possible for this group of men.”